Potensi Pravastatin sebagai Tata Laksana Preventif Preeklamsia di Indonesia

1. American College of Obstetricians and, Gynecologists. Gestational hypertension and preeclampsia. ACOG Pract Bull. 2019;133(1):1–25.

2. Cunningham FG, Leveno KJ, Bloom SL, Dashe JS, Hoffman BL, Casey BM, et al. Williams obstetrics. 25th ed. United States: McGraw-Hill Education; 2018.

3. Al-jameil N, Aziz F, Fareed M. A brief overview of preeclampsia. J Clin Med Res. 2014;6(1):1–7.

4. Kementerian Kesehatan RI. Infodatin: Mother’s day. Jakarta: Kementerian Kesehatan RI; 2014.

5. UNICEF. Trends in estimates of maternal mortality ratio (MMR; maternal deaths per 100,000 live births) [Internet]. UNICEF. 2020.

6. World Health Organization. Sdg 3: Ensure healthy lives and promote wellbeing for all at all ages [Internet]. World Health Organization. 2020 [cited 2020 Jan 12]; Available from: https://www.who.int/sdg/targets/en/

7. Perkumpulan Obstetri dan Ginekologi Indonesia Himpunan Kedokteran Feto Maternal. Diagnosis dan tata laksana preeklamsia. Jakarta: Perkumpulan Obstetri dan Ginekologi Indonesia Himpunan Kedokteran Feto Maternal; 2016.

8. Ahmed A, Williams D, Cheed V, Middleton L, Ahmad S, Wang K, et al. Pravastatin for early-onset pre-eclampsia : a randomised, blinded, placebo-controlled trial. BJOG. 2019;1:1–11.

9. Gajzlerska-majewska W, Bomba-opon DA, Wielgos M. Is pravastatin a milestone in the prevention and treatment of preeclampsia ?. J Perinat Med. 2018;46(8):825–31.

10. Akbar MIA, Yosediputra A, Pratama RE, Fadhilah NL, Sulistyowati S, Amani FZ, Ernawati E, Dachlan EG, Angsar MD, Dekker G. INOVASIA Study: A randomized open controlled trial to evaluate pravastatin to prevent preeclampsia and its effects on sFlt1/PlGF levels. Am J Perinatol. 2024 Feb;41(3):300-309. doi: 10.1055/a-1673-5603.

11. Costantine MM, Cleary K, Kennedy E. Pravastatin for the prevention of preeclampsia in high-risk pregnant women. Obs Gynecol. 2014;121(2):1–7.

12. Sammour MB, El-Kabarity H, Fawzy MM, Schindler a. E. Prevention and treatment of pre-eclampsia and eclampsia. Journal of Steroid Biochemistry & Molecular Biology. 2011; 97: 439–40.

13. Tolcher MC, Chu DM, Hollier LM, Mastrobattista JM, Racusin DA, Ramin SM, et al. Impact of USPSTF recommendations for aspirin for prevention of recurrent preeclampsia. Am J Obstet Gynecol [Internet]. 2017;217(3):365.e1-365.e8. Available from: http://dx.doi.org/10.1016/j.ajog.2017.04.035

14. Mészáros B, Veres DS, Nagyistók L, Somogyi A, Rosta K, Herold Z, Kukor Z and Valent S (2023) Pravastatin in preeclampsia: A meta-analysis and systematic review. Front. Med. 9:1076372. doi: 10.3389/fmed.2022.1076372

15. Tong S, Mol BW, Walker SP. Preventing preeclampsia with aspirin: does dose or timing matter? Am J Obstet Gynecol [Internet]. 2017;216(2):95–7. Available from: http://dx.doi.org/10.1016/j.ajog.2016.12.003

16. Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for Prevention of Preeclampsia. Drugs. 2017;77(17):1819–31.

17. Mone F, Mulcahy C, McParland P, Breathnach F, Downey P, McCormack D, et al. Trial of feasibility and acceptability of routine low-dose aspirin versus early screening test indicated aspirin for pre-eclampsia prevention (TEST study): A multicentre randomised controlled trial. BMJ Open. 2018;8(7):1–9

18. Huai J, Yang Z, Yi YH, Wang GJ. Different Effects of Pravastatin on Preeclampsia-like Symptoms in Different Mouse Models. Chin Med J (Engl). 2018;131(4):461–70.

19. Esteve-Valverde E, Ferrer-Oliveras R, Gil-Aliberas N, Baraldès-Farré A, Llurba E, Alijotas-Reig J. Pravastatin for Preventing and Treating Preeclampsia: A Systematic Review. Obstet Gynecol Surv. 2018;73(1):40–55.

20. Katsi V, Georgountzos G, Kallistratos MS, Zerdes I, Makris T, Manolis AJ, et al. The role of statins in prevention of preeclampsia: A promise for the future? Front Pharmacol. 2017;8(MAY):1–6.

21. Costantine MM, Tamayo E, Lu F, Bytautiene E, Longo M, Hankins GDV, et al. Using pravastatin to improve the vascular reactivity in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Obstet Gynecol. 2010;116(1):114–20.

22. Cleary KL, Roney K, Costantine M. Challenges of studying drugs in pregnancy for off-label indications: Pravastatin for preeclampsia prevention. Semin Perinatol [Internet]. 2014;38(8):523–7. Available from: http://dx.doi.org/10.1053/j.semperi.2014.08.019

23. Fox KA, Longo M, Tamayo E, Kechichian T, Bytautiene E, Hankins GDV, et al. Effects of pravastatin on mediators of vascular function in a mouse model of soluble Fms-like tyrosine kinase-1-induced preeclampsia. Am J Obstet Gynecol [Internet]. 2011;205(4):366.e1-366.e5. Available from: http://dx.doi.org/10.1016/j.ajog.2011.06.083

24. Costantine MM, Cleary K, Hebert MF, Ahmed MS, Brown LM, Ren Z, et al. Safety and pharmacokinetics of pravastatin used for the prevention of preeclampsia in high-risk pregnant women: A pilot randomized controlled trial. Am J Obstet Gynecol [Internet]. 2016;214(6):720.e1-720.e17. Available from: http://dx.doi.org/10.1016/j.ajog.2015.12.038

25. McDonnold M, Tamayo E, Kechichian T, Gamble P, Longo M, Hankins GDV, et al. The effect of prenatal pravastatin treatment on altered fetal programming of postnatal growth and metabolic function in a preeclampsia-like murine model. Am J Obstet Gynecol [Internet]. 2014;210(6):542.e1-542.e7. Available from: http://dx.doi.org/10.1016/j.ajog.2014.01.010

26. Nanovskaya TN, Patrikeeva SL, Paul J, Costantine MM, Hankins GDV, Ahmed MS. Transplacental transfer and distribution of pravastatin. Am J Obstet Gynecol [Internet]. 2013;209(4):373.e1-373.e5. Available from: http://dx.doi.org/10.1016/j.ajog.2013.05.038

27. Kräker K, O’Driscoll JM, Schütte T, Herse F, Patey O, Golic M, et al. Statins reverse postpartum cardiovascular dysfunction in a rat model of preeclampsia. American Heart Association. 2020;75(1):202–10.

28. Carver AR, Tamayo E, Perez-Polo JR, Saade GR, Hankins GD V, Costantine MM. The effect of maternal pravastatin therapy on adverse sensorimotor outcomes of the offspring in a murine model of preeclampsia. Int J Dev Neurosci [Internet]. 2014;33(1):33–40. Available from: http://dx.doi.org/10.1016/j.ijdevneu.2013.11.004

29. Girardi G. Pravastatin to treat and prevent preeclampsia. Preclinical and clinical studies. J Reprod Immunol [Internet]. 2017;124(July):15–20. Available from: http://dx.doi.org/10.1016/j.jri.2017.09.009

30. Tsur A, Kalish F, Burgess J, Nayak NR, Zhao H, Casey KM, et al. Pravastatin improves fetal survival in mice with a partial deficiency of heme oxygenase-1. Placenta [Internet]. 2019;75(July 2018):1–8. Available from: https://doi.org/10.1016/j.placenta.2018.11.001

31. Girardi G. Can statins prevent pregnancy complications? J Reprod Immunol [Internet]. s2014;101–102(1):161–7. Available from: http://dx.doi.org/10.1016/j.jri.2013.07.005

32. Pánczél Z, Kukor Z, Supák D, Kovács B, Kecskeméti A, Czizel R, et al. Pravastatin induces NO synthesis by enhancing microsomal arginine uptake in healthy and preeclamptic placentas. BMC Pregnancy Childbirth. 2019;19(1):1–9.

33. Garrett N, Pombo J, Umpierrez M, Clark JE, Simmons M, Girardi G. Pravastatin therapy during preeclampsia prevents long-term adverse health effects in mice. JCI insight. 2018;3(8):1–16.

34. Ramma W, Ahmed A. Therapeutic potential of statins and the induction of heme oxygenase-1 in preeclampsia. J Reprod Immunol [Internet]. 2014;101–102(1):153–60. Available from: http://dx.doi.org/10.1016/j.jri.2013.12.120

35. Saad AF, Kechichian T, Yin H, Sbrana E, Longo M, Wen M, et al. Effects of pravastatin on angiogenic and placental hypoxic imbalance in a mouse model of preeclampsia. Reprod Sci. 2014;21(1):138–45.

36. Carver AR, Andrikopoulou M, Lei J, Tamayo E, Gamble P, Hou Z, et al. Maternal pravastatin prevents altered fetal brain development in a preeclamptic CD-1 mouse model. PLoS One. 2014;9(6).

37. Otten LA, Van Der Ven K, Kühr M, Gembruch U, Merz WM. Pravastatin for prevention of HELLP syndrome. Med. 2017;96(42).

38. Marrs CC, Costantine MM. Should we add pravastatin to aspirin for preeclampsia preventio in high-risk women? Clin Obs Gynecol. 2017;60(1):161–8.

39. Lefkou E, Mamopoulos A, Fragakis N, Dagklis T, Vosnakis C, Nounopoulos E, et al. Clinical improvement and successful pregnancy in a preeclamptic patient with antiphospholipid syndrome treated with pravastatin. Hypertension. 2014;63(5):118–9.

40. Jurisic A, Jurisic Z, Lefkou E, Pombo J, Girardi G. Pravastatin and-L-arginine combination improves umbilical artery blood flow and neonatal outcomes in dichorionic twin pregnancies through an nitric oxide-dependent vasorelaxant effect. Vascul Pharmacol [Internet]. 2018;110(April):64–70. Available from: https://doi.org/10.1016/j.vph.2018.06.001

41. Chimini JS, Possomato-Vieira JS, da Silva MLS, Dias-Junior CA. Placental nitric oxide formation and endothelium-dependent vasodilation underlie pravastatin effects against angiogenic imbalance, hypertension in pregnancy and intrauterine growth restriction. Basic Clin Pharmacol Toxicol. 2019;124(4):385–93.

42. Brownfoot FC, Hannan N, Onda K, Tong S, Kaitu’U-Lino T. Soluble endoglin production is upregulated by oxysterols but not quenched by pravastatin in primary placental and endothelial cells. Placenta [Internet]. 2014;35(9):724–31. Available from: http://dx.doi.org/10.1016/j.placenta.2014.06.374

43. Brownfoot FC, Tong S, Hannan NJ, Binder NK, Walker SP, Cannon P, et al. Effects of Pravastatin on Human Placenta, Endothelium, and Women with Severe Preeclampsia. Hypertension. 2015;66(3):687–97.

44. Huai J, Yang Z, Yi YH, Wang GJ, Wang NN. Role of mammalian target of rapamycin signaling pathway in regulation of fatty acid oxidation in a preeclampsia-like mouse model treated with pravastatin. Chin Med J (Engl). 2019;132(6):671–9.

45. Saad AF, Diken ZM, Kechichian TB, Clark SM, Olson GL, Saade GR, et al. Pravastatin Effects on Placental Prosurvival Molecular Pathways in a Mouse Model of Preeclampsia. Reprod Sci. 2016;23(11):1593–9.

46. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: A systematic review. J Clin Lipidol [Internet]. 2016;10(5):1081–90. Available from: http://dx.doi.org/10.1016/j.jacl.2016.07.002

47. Lee MS, Hekimian A, Doctorian T, Duan L. Statin exposure during first trimester of pregnancy is associated with fetal ventricular septal defect. Int J Cardiol [Internet]. 2018;269:111–3. Available from: https://doi.org/10.1016/j.ijcard.2018.07.002

48. Costantine MM. Mini commentary Pravastatin to ameliorate early-onset pre-eclampsia : promising but not there yet. 2019;16067.

49. Liao JK. Safety and Efficacy of Statins in Asians. Am J Cardiol. 2007;99(3):410–4.

50. Kementrian Kesehatan Republik Indonesia. KEPMENKES Nomor 328/MENKES/SK/VIII/2013 tentang Formularium Nasional. 2013;53(9):1689–99